ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2397

Skin Lesions as a Side Effect of anti-IL6 Therapy: Transcriptome Analysis of Peripheral Blood Shows a Risk of Paradoxical Neutrophil Activation and Exacerbation of Skin Ulcer

Yoshinobu Koyama1, Akemi Senoo 2, Kaho Otsuki 3, Yoshiharu Sato 4, Mari Yamaguchi 2 and Toshie Higuchi 1, 1Center for Autoimmune Diseases, Division of Rheumatology, Japanese Red Cross Okayama Hospital, Okayama, Japan, 2Division of Dermatology, Japanese Red Cross Okayama Hospital, Okayama, Japan, 3Center for Autoimmune Diseases, Division of Rheumatology, Okayama, Japan, 4DNA Chip Research Inc, Tokyo, Japan

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: adverse events and Gene Expression, IL6, Rheumatoid arthritis (RA), Tocilizumab

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 12, 2019

Title: RA – Treatments Poster III: Safety and Outcomes

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Skin lesion as a side effect of Tocilizumab (TCZ) has not been paid much attention. In the drug information sheets, incidence of dermatological adverse reactions was only 1~2%. However, we experienced several RA cases with development of various skin lesions associated with neutrophil activation after TCZ therapy. Although the precise mechanism is still unclear, of particular interest is the decreased neutrophil counts in peripheral blood have been known after initiation of TCZ in clinical trials, which did not affect the rate of serious infections. On the other hand, we also experienced exacerbation of skin ulcer despite the inflammation, such as activity of rheumatoid arthritis, was absolutely under control. In this study, we try to detect the changes in transcriptome of peripheral blood after TCZ treatment.

Methods: As total of 23 RA cases (43.2 person-years) was completely followed in our single hospital from the initiation of TCZ, their medical records were checked to calculate the incidence of dermatological adverse reactions to TCZ from 2014 to 2018. Meanwhile, to explore the normal response to anti-IL6 therapy, peripheral whole blood at just before (pre) and 3 months after (post) TCZ treatment from 10 RA cases without any dermatological problems were subjected to gene expression study. Total RNAs were then extracted with PAXgene miRNA kit. After quantifying the transcripts, differentially expressed genes (DEGs) were selected by paired comparison (post vs. pre), setting thresholds at 2-fold change up/down and less than P=0.05 in paired T-test. And then, enrichment analysis using gene ontology (GO) terms were performed.

Results: Among 23 patients, 4 cases (9.25/100 person-years) of Skin lesion including neutrophilic dermatosis and leukocytoclastic vasculitis were observed as side effects of TCZ. Although 2 of them required termination of the therapy, others were possible to continue TCZ treatment. We also experienced 2 cases of exacerbation of skin ulcer despite the inflammation was under favorable control. For transcriptome analysis, total of 57571 transcripts were identified and the 52/156 genes of up/down-regulated genes were selected as DEGs from the comparison of post vs. pre treatment of TCZ using paried T-test. Surprisingly, 8 out of the top 10 enriched GO terms in the up-regulated genes were relevant to leukocyte activation such as ‘neutrophil chemotaxis’. On the other hand, 6 out of the top 10 enriched GO terms in the down-regulated genes were related to tissue repair, such as “platelet activation” and “wound healing”.

Conclusion: As the cytokine network is very complicated and an exquisite balance presented in immune and homeostatic system is strictly maintained, inhibition of a multifunctional cytokine signaling such as IL-6 may cause unexpected adverse reactions. Our findings indicate a potential risk of the development of skin lesions associated with neutrophil activation by anti-IL6 therapy. The mechanism may also help the increased margination of neutrophils in normal situation, and it may be a hint for the secret behind the decreased neutrophil counts after TCZ treatment. Anyway, we will not recommend anti-IL6 therapy for the patients with skin ulcers from our experiences.


Disclosure: Y. Koyama, Ayumi, 8, BMS, 8, Chugai, 8, Asahi-Kasei, 8, Lilly, 8, Tanabe-Mitsubishi, 8; A. Senoo, None; K. Otsuki, None; Y. Sato, None; M. Yamaguchi, None; T. Higuchi, None.

To cite this abstract in AMA style:

Koyama Y, Senoo A, Otsuki K, Sato Y, Yamaguchi M, Higuchi T. Skin Lesions as a Side Effect of anti-IL6 Therapy: Transcriptome Analysis of Peripheral Blood Shows a Risk of Paradoxical Neutrophil Activation and Exacerbation of Skin Ulcer [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/skin-lesions-as-a-side-effect-of-anti-il6-therapy-transcriptome-analysis-of-peripheral-blood-shows-a-risk-of-paradoxical-neutrophil-activation-and-exacerbation-of-skin-ulcer/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/skin-lesions-as-a-side-effect-of-anti-il6-therapy-transcriptome-analysis-of-peripheral-blood-shows-a-risk-of-paradoxical-neutrophil-activation-and-exacerbation-of-skin-ulcer/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology